VNDA Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
50.5M
-2.3%
51.7M
-9.6%
57.2M
+1.7%
56.3M
+7.0%
52.6M
Cost of Revenue
3.6M
+12.7%
3.2M
-17.6%
3.8M
+29.8%
3.0M
+8.0%
2.7M
Gross Profit
47.0M
-3.3%
48.6M
-9.0%
53.4M
+0.1%
53.3M
+6.9%
49.9M
Operating Expenses
110.8M
+12.1%
98.8M
+5.4%
93.7M
+10.8%
84.6M
-4.3%
88.4M
R&D
37.0M
+30.0%
28.4M
-2.0%
29.0M
+28.6%
22.6M
+2.6%
22.0M
SG&A
71.8M
+5.1%
68.4M
+8.5%
63.0M
+4.5%
60.3M
-6.7%
64.6M
Operating Income
-63809000
-27.0%
-50224000
-24.5%
-40353000
-29.0%
-31284000
+18.7%
-38503000
EBITDA
-61555000
-28.3%
-47964000
-25.2%
-38297000
-31.0%
-29231000
+19.9%
-36485000
Net Income
-62513000
-28.7%
-48567000
+65.6%
-141187000
-525.1%
-22586000
+17.0%
-27207000
EPS (Basic)
$-1.04
-26.8%
$-0.82
+65.7%
$-2.39
-528.9%
$-0.38
+17.4%
$-0.46
EPS (Diluted)
$-1.04
-26.8%
$-0.82
+65.7%
$-2.39
-528.9%
$-0.38
+17.4%
$-0.46
Shares (Diluted)
60.2M
+1.3%
59.5M
+0.6%
59.1M
+0.0%
59.1M
+0.2%
59.0M
Vanda Pharmaceuticals (VNDA) โ€” Financials